ABSTRACT
Introduction: This study aimed to explore the factors influencing people's utilization of ride-hailing services, particularly in the context of the COVID-19 pandemic. Methods: A two-stage survey was conducted among the same group of passengers pre and post COVID-19 pandemic, resulting in a total of 670 valid samples. Exploratory factor analysis (EFA) was applied to the data, followed by the ordered probit and ordered logit models to identify the motivational factors behind passengers' frequency of using ride-hailing. Results: The findings indicated that trust and loyalty were the most influential factors in determining passengers' frequency of using ride-hailing services. However, passengers' perception of the COVID-19 pandemic did not have a significant effect on the frequency of using ride-hailing. Discussion: This research provides empirical evidence and policy implications for understanding people's usage of the ride-hailing services in the context of public-health emergency.
Subject(s)
COVID-19 , Humans , COVID-19/epidemiology , Pandemics , Surveys and Questionnaires , Motivation , TrustABSTRACT
PURPOSE: This paper was intended to describe the characteristics of coronavirus disease 2019 (COVID-19) patients with known chronic kidney disease (CKD) history. METHODS: Clinical information of 20 COVID-19 pneumonia patients with CKD history diagnosed between January 20th and March 1st, 2020 were collected in Tongji Hospital, Wuhan. We listed the clinical baseline data, laboratory findings, chest computed tomography (CT) changes and processed a short period of follow-up of these 20 patients. RESULTS: Based on the estimated glomerular filtration rate (eGFR) on admission, 6 patients were classified as stage 2 of CKD, 5 were as 3a, 2 were as 3b, 3 were as 4 and 4 were as 5, respectively. COVID-19 patients with CKD history were elder and hypertension was the most common comorbidity. Cough and fever accounted for more than 80% of the infectious cases. Lymphopenia, increased D-dimer and elevated infectious indications such as hypersensitive C response protein (hsCRP), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) were also common among these patients. Ground-glass opacity (GGO) and consolidation were the major manifestations in CT scans. 4 patients died and 7 patients underwent acute kidney injury (AKI) during observation. Among 16 discharged patients, 12 were with stable renal function and 4 had deteriorating renal function compared with that of admission. CONCLUSION: Compared to general population infected with SARS-CoV-2, COVID-19 patients with CKD history had a preference to develop to severity with higher fatality rate.
Subject(s)
COVID-19/epidemiology , Hospitalization/statistics & numerical data , Pandemics , Renal Insufficiency, Chronic/epidemiology , Aged , Aged, 80 and over , COVID-19/diagnosis , China/epidemiology , Comorbidity , Female , Humans , Male , Middle Aged , Renal Insufficiency, Chronic/diagnosis , Retrospective Studies , SARS-CoV-2 , Survival Rate/trends , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Bromhexine hydrochloride tablets may be effective in the treatment of Coronavirus disease 2019 (COVID-19) in children. This study will further evaluate the efficacy and safety of bromhexine hydrochloride tablets in the treatment of COVID-19 in children. METHODS: The following electronic databases will be searched, with all relevant randomized controlled trials (RCTs) up to August 2020 to be included: PubMed, Embase, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), the Chongqing VIP China Science and Technology Database (VIP), Wanfang, the Technology Periodical Database, and the Chinese Biomedical Literature Database (CBM). As well as the above, Baidu, the International Clinical Trials Registry Platform (ICTRP), Google Scholar, and the Chinese Clinical Trial Registry (ChiCTR) will also be searched to obtain more comprehensive data. Besides, the references of the included literature will also be traced to supplement our search results and to obtain all relevant literature. RESULTS: This systematic review will evaluate the current status of bromhexine hydrochloride in the treatment of COVID-19 in children, to evaluate its efficacy and safety. CONCLUSION: This study will provide the latest evidence for evaluating the efficacy and safety of bromhexine hydrochloride in the treatment of COVID-19 in children. PROSPERO REGISTRATION NUMBER: CRD42020199805. ETHICS AND DISSEMINATION: The private information of individuals will not be published. This systematic review will also not involve endangering participant rights. Ethical approval is not available. The results may be published in peer-reviewed journals or disseminated at relevant conferences.
Subject(s)
Bromhexine/pharmacology , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Betacoronavirus , COVID-19 , Child , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Expectorants/pharmacology , Humans , Meta-Analysis as Topic , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , Research Design , SARS-CoV-2 , Systematic Reviews as Topic , Treatment OutcomeABSTRACT
Pregnant women with 2019 novel coronavirus disease (COVID-19) pneumonia are a special group of patients in the pandemic. We report a case of pregnant woman with COVID-19 pneumonia in the second trimester. Clinical and imaging features of the patient were similar to that reported in the literatures for both perinatal patients and non-pregnant patients.